AdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(2), С. 484 - 484

Опубликована: Янв. 8, 2025

Alzheimer's disease (AD) remains a leading cause of cognitive decline and mortality worldwide, characterized by neurodegeneration, synaptic deficiencies, neuroinflammation. Despite advancements in early detection, diagnosis, treatment, AD presents substantial challenges due to its complex pathology, heterogeneity, the limited efficacy current therapies. Consequently, there is pressing need for novel therapeutic agents target multifaceted aspects enhance treatments, minimize adverse effects. AdipoRon, an adiponectin receptor agonist, has garnered interest potential neuroprotective effects, including reducing neuroinflammation, improving mitochondrial function, mitigating tau hyperphosphorylation. This review aimed evaluate effects AdipoRon-based replacement therapy against AD, using comprehensive approach grounded PICO framework-Population, Intervention, Comparison, Outcomes. A total six studies were reviewed, vitro vivo investigations examining AdipoRon's impact on various models. These involved different cell lines transgenic mouse models, assessing outcomes such as phosphorylation, relevant molecular pathways. By synthesizing data from these studies, our thoroughly explains mechanisms action, agent AD. analysis aims highlight state knowledge, identify gaps research, suggest directions future clinical applications.

Язык: Английский

---

MicroRNAs in Parkinson’s disease: From pathogenesis to diagnostics and therapeutic strategies

Neuroscience, Год журнала: 2025, Номер unknown

Опубликована: Янв. 1, 2025

Язык: Английский

---

rTMS ameliorates CUMS-induced anxiety-depression-like behaviour and cognitive dysfunction in rats by modulating the COX-2/PGE2 signalling pathway

Journal of Psychiatric Research, Год журнала: 2025, Номер unknown

Опубликована: Апрель 1, 2025

Язык: Английский

---

Nose-to-brain drug delivery: from bench to bedside

Translational Neurodegeneration, Год журнала: 2025, Номер 14(1)

Опубликована: Май 19, 2025

Abstract There is increasing interest in nose-to-brain delivery as an innovative drug strategy for neurodegenerative disorders such Parkinson’s or Alzheimer’s disease. The unique anatomy of the nose-brain interface facilitates direct transport via olfactory and trigeminal pathways to brain, bypassing blood–brain barrier. Different administration techniques well advanced formulations like targeted nanoparticles thermoresponsive systems have been explored improve efficiency therapeutic efficacy. This review provides up-to-date perspective on this fast-developing field, discusses different studies safety pharmacokinetic properties. A thorough evaluation preclinical clinical reveals both promises challenges method, highlighting approved drugs treatment epilepsy migraine that successfully utilize intranasal routes. current landscape research critically discussed, a rationale provided ongoing optimize strategies.

Язык: Английский

---

Intranasal AdipoRon mitigates motor and cognitive deficits in hemiparkinsonian rats through neuroprotective mechanisms against oxidative stress and synaptic dysfunction

Neuropharmacology, Год журнала: 2024, Номер 262, С. 110180 - 110180

Опубликована: Окт. 10, 2024

Язык: Английский

---